CL2012000783A1 - Proceso para mejorar la eficacia de proteccion metodo para inducir una respuesta inmune contra el virus del dengue que comprende vacunas de dna y virus quimericos 17d; composicion vacunal que comprende vacunas de dna contra los cuatro serotipos del virus dengue y virus quimericos comprendiendo el virus vacunal de fiebre amarilla; plasmido recombinante conteniendo el gen de la proteína e. - Google Patents
Proceso para mejorar la eficacia de proteccion metodo para inducir una respuesta inmune contra el virus del dengue que comprende vacunas de dna y virus quimericos 17d; composicion vacunal que comprende vacunas de dna contra los cuatro serotipos del virus dengue y virus quimericos comprendiendo el virus vacunal de fiebre amarilla; plasmido recombinante conteniendo el gen de la proteína e.Info
- Publication number
- CL2012000783A1 CL2012000783A1 CL2012000783A CL2012000783A CL2012000783A1 CL 2012000783 A1 CL2012000783 A1 CL 2012000783A1 CL 2012000783 A CL2012000783 A CL 2012000783A CL 2012000783 A CL2012000783 A CL 2012000783A CL 2012000783 A1 CL2012000783 A1 CL 2012000783A1
- Authority
- CL
- Chile
- Prior art keywords
- dna vaccines
- virus
- chimeric viruses
- dengue virus
- serotypes
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 6
- 108010041986 DNA Vaccines Proteins 0.000 title abstract 4
- 229940021995 DNA vaccine Drugs 0.000 title abstract 4
- 241000725619 Dengue virus Species 0.000 title abstract 4
- 230000028993 immune response Effects 0.000 title abstract 2
- 239000013612 plasmid Substances 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 229960001515 yellow fever vaccine Drugs 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title 2
- 102000004169 proteins and genes Human genes 0.000 title 1
- 101710204837 Envelope small membrane protein Proteins 0.000 abstract 1
- 101710088839 Replication initiation protein Proteins 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Método para inducir una respuesta inmune contra el virus del dengue que comprende vacunas de DNA y virus quiméricos 17D; composición vacunal que comprende vacunas de DNA contra los cuatro serotipos del virus dengue y virus quiméricos comprendiendo el virus vacunal de fiebre amarilla; plasmido recombinante conteniendo el gen de la proteína E.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0904020A BRPI0904020B8 (pt) | 2009-10-01 | 2009-10-01 | composição vacinal contra o vírus da dengue, e, kit |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2012000783A1 true CL2012000783A1 (es) | 2013-03-22 |
Family
ID=43825448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2012000783A CL2012000783A1 (es) | 2009-10-01 | 2012-03-29 | Proceso para mejorar la eficacia de proteccion metodo para inducir una respuesta inmune contra el virus del dengue que comprende vacunas de dna y virus quimericos 17d; composicion vacunal que comprende vacunas de dna contra los cuatro serotipos del virus dengue y virus quimericos comprendiendo el virus vacunal de fiebre amarilla; plasmido recombinante conteniendo el gen de la proteína e. |
Country Status (10)
Country | Link |
---|---|
US (1) | US10357558B2 (es) |
EP (1) | EP2484376A4 (es) |
CN (1) | CN102711817B (es) |
BR (1) | BRPI0904020B8 (es) |
CL (1) | CL2012000783A1 (es) |
CO (1) | CO6541529A2 (es) |
CU (1) | CU24060B1 (es) |
EC (1) | ECSP12012131A (es) |
PE (2) | PE20121171A1 (es) |
WO (1) | WO2011038473A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2933970T3 (es) | 2013-03-15 | 2023-02-15 | Takeda Vaccines Inc | Composiciones y métodos para construcciones quiméricas de virus del dengue en vacunas |
AU2014281713A1 (en) | 2013-06-21 | 2015-11-12 | Merck Sharp & Dohme Corp. | Dengue virus vaccine compositions and methods of use thereof |
ITRM20130458A1 (it) | 2013-08-05 | 2015-02-05 | Internat Ct For Genetic En Gineering And | Vaccino genetico anti-dengue virus basato sugli ectodomini della proteina envelope |
US10449243B2 (en) | 2014-12-22 | 2019-10-22 | Merck Sharp & Dohme Corp. | Dengue virus vaccine compositions and methods of use thereof |
US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
CA3111332A1 (en) | 2018-09-05 | 2020-03-12 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6455509B1 (en) * | 1996-06-04 | 2002-09-24 | The United States Of America As Represented By The Secretary Of The Navy | Dengue nucleic acid vaccines that induce neutralizing antibodies |
US6962708B1 (en) * | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
BRPI9701774B8 (pt) | 1997-04-11 | 2015-09-29 | Fundação Oswaldo Cruz Fiocruz | cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela. |
US6881723B1 (en) * | 1998-11-05 | 2005-04-19 | Powderject Vaccines, Inc. | Nucleic acid constructs |
AU2003267943C1 (en) * | 2002-02-26 | 2009-05-21 | Altravax, Inc. | Novel flavivirus antigens |
CN101287490B (zh) * | 2005-08-10 | 2013-04-24 | 阿坎姆比斯公司 | 对抗登革热病毒感染的疫苗接种 |
WO2007021672A2 (en) | 2005-08-10 | 2007-02-22 | Acambis Inc. | Vaccination against dengue virus infection |
CU23586A1 (es) * | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
US8241638B2 (en) * | 2006-11-09 | 2012-08-14 | The United States Of America As Represented By The Secretary Of The Navy | Induction of an immune response against dengue virus using the prime-boost approach |
EP2234624B1 (en) * | 2008-01-11 | 2018-06-20 | Inovio Pharmaceuticals, Inc. | Novel vaccines against multiple subtypes of dengue virus |
-
2009
- 2009-10-01 BR BRPI0904020A patent/BRPI0904020B8/pt active IP Right Grant
-
2010
- 2010-08-01 US US13/499,697 patent/US10357558B2/en not_active Expired - Fee Related
- 2010-08-01 PE PE2012000411A patent/PE20121171A1/es active IP Right Grant
- 2010-08-01 PE PE2016001214A patent/PE20161094A1/es unknown
- 2010-08-01 WO PCT/BR2010/000323 patent/WO2011038473A1/pt active Application Filing
- 2010-08-01 CN CN201080052438.4A patent/CN102711817B/zh active Active
- 2010-08-01 EP EP10819756.7A patent/EP2484376A4/en not_active Withdrawn
-
2012
- 2012-03-29 CL CL2012000783A patent/CL2012000783A1/es unknown
- 2012-04-02 CU CU20120057A patent/CU24060B1/es active IP Right Grant
- 2012-04-26 CO CO12069004A patent/CO6541529A2/es unknown
- 2012-05-04 EC ECSP12012131 patent/ECSP12012131A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN102711817A (zh) | 2012-10-03 |
PE20161094A1 (es) | 2016-10-22 |
PE20121171A1 (es) | 2012-08-30 |
EP2484376A1 (en) | 2012-08-08 |
WO2011038473A8 (pt) | 2012-07-19 |
ECSP12012131A (es) | 2013-02-28 |
US10357558B2 (en) | 2019-07-23 |
BRPI0904020B1 (pt) | 2019-11-12 |
EP2484376A4 (en) | 2014-01-22 |
CO6541529A2 (es) | 2012-10-16 |
US20120251570A1 (en) | 2012-10-04 |
CU24060B1 (es) | 2014-12-26 |
CN102711817B (zh) | 2016-10-26 |
BRPI0904020B8 (pt) | 2021-05-25 |
WO2011038473A1 (pt) | 2011-04-07 |
BRPI0904020A2 (pt) | 2011-06-14 |
CU20120057A7 (es) | 2013-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2012000783A1 (es) | Proceso para mejorar la eficacia de proteccion metodo para inducir una respuesta inmune contra el virus del dengue que comprende vacunas de dna y virus quimericos 17d; composicion vacunal que comprende vacunas de dna contra los cuatro serotipos del virus dengue y virus quimericos comprendiendo el virus vacunal de fiebre amarilla; plasmido recombinante conteniendo el gen de la proteína e. | |
BR112018017307A2 (pt) | molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus | |
CR20170174A (es) | Composiciones y métodos para el silenciamiento de la expresión cénica del virus de la hepatitis b | |
AR080313A1 (es) | Composiciones de virus de moquillo canino (cdv) recombinante y sus usos | |
CL2012000447A1 (es) | Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica. | |
AR090401A1 (es) | Vectores recombinantes de herpesvirus 3 galido (mdv serotipo 2) que expresan antigenos de patogenos de aves y sus usos | |
CO2017007105A2 (es) | Nuevos virus de tilapia | |
CR20140189S (es) | Vacunas y metodos para crear una vacuna para inducir la inmunidad a todos los serotipos del virus del dengue | |
AR087772A1 (es) | Un citomegalovirus de replicacion condicionada como vacuna contra el cmv | |
CL2019000704A1 (es) | Vectores de adenovirus canino. | |
CO7461133A2 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
CO6761335A2 (es) | Inhibidores del virus de la hepatitis c | |
AR079767A1 (es) | Antigeno ndv (virus de la enfermedad de newcastle) recombinante y usos del mismo | |
UY33297A (es) | Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas | |
CR20140069A (es) | Formulaciones parenterales de vacunas contra los norovirus | |
NZ630869A (en) | Compositions and methods for dengue virus chimeric constructs in vaccines | |
CO6440541A2 (es) | Virus de diarrea viral bovina con una proteina erns modificada | |
CU24580B1 (es) | Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas | |
CO6470882A2 (es) | Composiciones y metodos para administración de vacunas contra virus del dengue. | |
BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
CO7461135A2 (es) | Parvovirus porcino 5b, métodos de uso y vacuna | |
NI201700080A (es) | Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas. | |
ME01270B (me) | Cjepiva protiv zaraznog bronhitisa dobivena iz sojeva virusa sličnog ib-qx | |
BRPI0916186B8 (pt) | vetor de plasmídeo e seu uso, vacina para febre amarela e para vírus de rna infeccioso e vírus atenuado vivo clonalmente purificado homogêneo e seu uso | |
AR066823A1 (es) | Aumento del rendimiento en plantas por modulacion del factor zmrr10-p de transcripcion de garp |